Industry gives cautious welcome to EU animal testing vote
This article was originally published in Scrip
The European biopharmaceutical industry has given a cautious welcome to a report on a draft directive amending the rules on the protection of laboratory animals, which was approved by the European Parliament on May 5th and now goes for discussion by the EU member states.
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.